- Investing Ideas
- Danish Pharmaceuticals & Biotech Potentially Undervalued Companies
Danish Pharmaceuticals & Biotech Potentially Undervalued Companies
Results
7
Companies with a Value score of at least 3, ordered by Value score
7 companies
Bavarian Nordic
Market Cap: DKK 14.0b
Develops, manufactures, and supplies life-saving vaccines.
BAVA
DKK 182.80
7D
4.5%
1Y
-23.4%
H. Lundbeck
Market Cap: DKK 40.4b
Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
HLUN B
DKK 42.00
7D
1.2%
1Y
7.9%
Novo Nordisk
Market Cap: DKK 1.3t
Engages in the research and development, manufacture, and distribution of pharmaceutical products.
NOVO B
DKK 298.25
7D
1.6%
1Y
-8.1%
H. Lundbeck
Market Cap: DKK 40.4b
Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
HLUN A
DKK 35.80
7D
0.6%
1Y
9.5%
Gubra
Market Cap: DKK 6.2b
A disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally.
GUBRA
DKK 380.80
7D
5.2%
1Y
9.5%
Genmab
Market Cap: DKK 120.9b
A biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
GMAB
DKK 2,025.00
7D
7.9%
1Y
38.8%
Zealand Pharma
Market Cap: DKK 23.7b
A biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States.
ZEAL
DKK 341.20
7D
3.9%
1Y
-2.6%